Vaxcyte (PCVX) AI Stock Analysis

• Market Cap: $5.93B
• Dividend Yield: N/A
• Average Volume (3M): 1.29M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.58
• Revenue Growth: N/A
• EPS Growth: -5.21%
• Country: US
• Employees: 414
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.56
• Shares Outstanding: 130,906,270
• 10 Day Avg. Volume: 936,274
• 30 Day Avg. Volume: 1,287,771
• PEG Ratio: 2.62
• Price to Book (P/B): 3.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -21.02
• Enterprise Value/Market Cap: 0.55
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -657.23
• Enterprise Value/Ebitda: -5.47
• 1Y Price Target: $104.80
• Price Target Upside: 131.24% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $47.00 ▲(3.71% Upside)

The score is held back primarily by weak financial performance (no revenue, widening losses, and heavy cash burn), partially offset by a strong low-debt balance sheet. Technicals are moderately constructive with price above key moving averages and neutral momentum, while valuation is constrained by ongoing losses. Corporate events add a small positive tilt through manufacturing readiness, tempered by higher executive severance obligations.

Positive Factors

Strong Financial Position

A robust cash position provides Vaxcyte with the necessary resources to fund R&D and operational activities, supporting long-term growth and stability.

Pipeline Advancements

Successful clinical trial advancements enhance Vaxcyte's competitive position and potential market share in the vaccine industry.

Manufacturing Expansion

Expanding manufacturing capabilities ensures Vaxcyte can meet future demand, supporting scalability and long-term supply chain efficiency.

Negative Factors

Increased Expenses

Rising expenses can strain financial resources, potentially impacting profitability and necessitating further financing to sustain operations.

Regulatory Uncertainty

Regulatory changes can affect market access and demand for Vaxcyte's products, posing risks to strategic planning and revenue projections.

Challenges in Achieving Non-Inferiority

Failure to meet clinical benchmarks could delay product launches and reduce competitive advantage, impacting long-term growth prospects.

Vaxcyte Business Overview & Revenue Model

Company Description

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

How the Company Makes Money

Vaxcyte makes money primarily through the development and commercialization of its vaccine candidates. The company's revenue model involves research and development (R&D) investments to advance its vaccine pipeline through clinical trials, regulatory approval, and ultimately, market launch. Key revenue streams include potential product sales, milestone payments, and royalties from partnerships or licensing agreements with other pharmaceutical companies. Additionally, Vaxcyte may benefit from government grants or funding to support vaccine development. Strategic collaborations with industry partners can also contribute to its earnings by sharing development costs and expanding market reach upon commercialization.

Vaxcyte Financial Statement Overview

Summary

Vaxcyte is in a typical financial position for a biotech firm at its stage: no revenue, significant R&D investment, and reliance on financing to maintain liquidity. The strong equity base and cash reserves provide a buffer against short-term challenges, but the company needs to transition to revenue generation to improve its financial health in the long term.

Income Statement

Vaxcyte has consistently reported no revenue, which is typical for early-stage biotechnology companies focusing on product development. The company has a negative EBIT and EBITDA, indicating ongoing operational losses. The net income has been negative over the years, reflecting substantial R&D and operating expenses without offsetting revenue. However, this is a standard profile for a biotech firm in the development phase.

Balance Sheet

The company's balance sheet shows strong liquidity, with cash and short-term investments significantly exceeding total debt, resulting in a negative net debt. The stockholders' equity is robust, and the equity ratio is high, indicating financial stability. However, the lack of revenue generation and increasing liabilities over time are potential concerns if the trend continues without revenue.

Cash Flow

Operating cash flow is negative, reflecting the company's pre-revenue stage and heavy investment in R&D. Free cash flow is also negative, though financing activities have been strong, suggesting continued investor confidence. The company has maintained its cash position through financing, offsetting the negative cash flow from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-4.99M	0.00	0.00	0.00	0.00	-1.41M
EBITDA	-599.85M	-448.08M	-392.10M	-214.03M	-96.61M	-87.81M
Net Income	-657.20M	-463.93M	-402.27M	-223.49M	-100.08M	-89.22M
Balance Sheet
Total Assets	3.17B	3.51B	1.41B	1.01B	324.34M	392.83M
Cash, Cash Equivalents and Short-Term Investments	1.71B	1.75B	1.08B	931.38M	245.97M	386.20M
Total Debt	84.44M	71.11M	29.22M	17.94M	16.78M	0.00
Total Liabilities	278.72M	205.50M	167.45M	52.56M	40.32M	46.98M
Stockholders Equity	2.89B	3.31B	1.24B	953.61M	284.02M	345.84M
Cash Flow
Free Cash Flow	-591.45M	-475.05M	-364.67M	-176.44M	-127.95M	-47.78M
Operating Cash Flow	-542.15M	-452.63M	-296.79M	-170.60M	-121.39M	-46.63M
Investing Cash Flow	-234.94M	-2.01B	-773.31M	74.58M	-212.31M	-1.10M
Financing Cash Flow	4.51M	2.45B	639.81M	861.55M	17.80M	374.87M

Vaxcyte Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 45.32
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PCVX, the sentiment is Neutral. The current price of 45.32 is below the 20-day moving average (MA) of 45.56, below the 50-day MA of 45.76, and above the 200-day MA of 37.81, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 47.97 is Neutral, neither overbought nor oversold. The STOCH value of 34.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PCVX.

Vaxcyte Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KRYS	79 Outperform	$7.22B	37.33	19.66%	―	54.51%	275.94%
PTCT	68 Neutral	$6.17B	8.98	―	―	97.54%	―
PCVX	52 Neutral	$5.93B	-9.21	-20.83%	―	―	-5.21%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ZLAB	48 Neutral	$2.08B	-9.49	-28.96%	―	23.73%	30.16%
ACLX	40 Underperform	$3.72B	-16.41	-47.18%	―	-76.96%	-425.41%

Vaxcyte Corporate Events

Vaxcyte Enhances Executive Severance to Align With Market

On December 18, 2025, Vaxcyte amended existing executive change in control and severance agreements for its top executives, following approval by the board’s compensation committee as part of its annual compensation review and planning process. Effective December 31, 2025, the company will increase base salary, bonus and COBRA coverage severance multipliers for CEO Grant Pickering and for President and CFO Andrew Guggenhime, COO Jim Wassil and CTO Harpreet Dhaliwal, both for standard qualifying terminations and for change-in-control-related terminations, in order to bring executive severance levels more in line with market peers and potentially strengthen leadership retention and alignment with shareholder interests.

The most recent analyst rating on (PCVX) stock is a Buy with a $85.00 price target. To see the full list of analyst forecasts on Vaxcyte stock, see the PCVX Stock Forecast page.